March 12 (Reuters) - Ultragenyx Pharmaceutical said on Thursday its experimental gene therapy helped patients in a late-stage trial to better control ammonia levels linked to a rare inherited disorder ...
Enh3ance trial results indicate DTX301 reduces ammonia levels by 18% and supports dietary liberalization in patients with OTC deficiency.
Ultragenyx Pharmaceutical Inc. RARE shares are down on Thursday as the company reported data from its Phase 3 study of DTX301 ...
Ultragenyx Pharma (RARE) stock is in focus as gene therapy DTX301 met its main goal in a late-stage trial for the most common ...
Ammonia buildup may speed hepatocellular carcinoma in mice. Read more to see how a low-protein diet could slow tumour growth.
High levels of ammonia in tumors lead to fewer T cells and immunotherapy resistance in mouse models of colorectal cancer, new findings from the University of Michigan Rogel Cancer Center revealed.
The SERVOTOUGH Laser 3 Plus Environmental uses tunable diode laser technology to deliver ammonia measurements.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results